Clinical Trials Browser

Phase 2/3 × Completed × AZD4547 × Clear all

NCT02965378 2021-05-27

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Phase 2/3 Completed

43 enrolled 15 charts

FGFR1 Gene Amplification